Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 32.15M | 28.52M | 7.16M | 0.00 | 6.25M | 79.11M |
Gross Profit | 32.09M | 28.39M | -41.74M | -498.00K | 5.79M | 79.00M |
EBITDA | -44.50M | -45.42M | -64.20M | -92.59M | -91.93M | -64.78M |
Net Income | -39.92M | -40.18M | -61.23M | -92.07M | -129.85M | -59.53M |
Balance Sheet | ||||||
Total Assets | 99.02M | 119.17M | 136.82M | 101.79M | 191.06M | 283.25M |
Cash, Cash Equivalents and Short-Term Investments | 91.03M | 112.08M | 130.25M | 91.61M | 146.63M | 216.41M |
Total Debt | 3.02M | 3.09M | 2.34M | 3.46M | 6.48M | 10.13M |
Total Liabilities | 71.88M | 85.81M | 95.73M | 19.13M | 22.13M | 42.68M |
Stockholders Equity | 27.13M | 33.36M | 41.10M | 82.66M | 168.93M | 240.58M |
Cash Flow | ||||||
Free Cash Flow | -56.21M | -51.15M | 22.49M | -84.56M | -96.49M | -65.18M |
Operating Cash Flow | -56.19M | -51.12M | 22.74M | -84.46M | -93.40M | -62.96M |
Investing Cash Flow | 29.48M | 40.17M | -69.14M | 90.64M | 26.52M | 68.07M |
Financing Cash Flow | 31.37M | 29.45M | 13.82M | 614.00K | 53.06M | 7.60M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $138.55M | ― | -133.65% | ― | 148.33% | 42.41% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
$61.31M | ― | -20.33% | ― | ― | ― | ||
41 Neutral | $148.02M | ― | -46.04% | ― | ― | 39.58% | |
36 Underperform | $70.27M | ― | -55.68% | ― | ― | -57.45% | |
32 Underperform | $33.85M | ― | -1372.59% | ― | ― | 20.85% | |
$69.50M | ― | -54.30% | ― | ― | ― |
On June 25, 2025, Assembly Biosciences announced positive topline results from a Phase 1b clinical trial evaluating ABI-4334, a next-generation capsid assembly modulator, in participants with chronic hepatitis B virus infection. The trial demonstrated favorable safety, tolerability, and pharmacokinetics, supporting once-daily oral dosing. The results showed significant antiviral activity, with mean plasma HBV DNA reductions consistent across different dosage cohorts. These findings support the potential of ABI-4334 to inhibit viral replication and cccDNA formation, crucial for HBV treatment regimens. The completion of the trial triggers an opt-in point for collaboration with Gilead Sciences, Inc., which could impact future development and commercialization efforts.
The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.
At the Annual Meeting of Stockholders on June 5, 2025, Assembly Biosciences, Inc. announced the approval of amendments to its 2018 Stock Incentive Plan and Employee Stock Purchase Plan, increasing the number of shares reserved for issuance. These amendments aim to enhance the company’s retention grant program and support employee stock purchases, reflecting a strategic move to bolster employee engagement and retention. Additionally, Jeanette M. Bjorkquist was appointed as the principal financial officer, succeeding Jason A. Okazaki, who remains the principal executive officer. This management change signifies a continued focus on strengthening the company’s financial leadership.
The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.